Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tatsushi Wakayama"'
Autor:
Hiroki Hayase, Shinsaku Itou, Tatsuya Horio, Tomohiro Hamasaki, Toshihiko Inoue, Tomoko Niwa, Tetsuo Asaki, Haruna Naito, Tatsushi Wakayama
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:2712-2717
To investigate why 3-substituted benzamide derivatives show dual inhibition of Abl and Lyn protein tyrosine kinases, we determined their inhibitory activities against Abl and Lyn, carried out molecular modeling, and conducted a structure-activity rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c8f869f000a245e129f7d5f0cea388e
https://doi.org/10.1016/j.bmcl.2007.03.002
https://doi.org/10.1016/j.bmcl.2007.03.002
Autor:
Shinsaku Ito, Kazuko Hirabayashi, Taira Maekawa, Shinya Kimura, Sachie Kimura, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Haruna Naito
Publikováno v:
Leukemia Research. 30:1443-1446
Advanced-phase chronic myeloid leukemia patients treated with imatinib often relapse due to point mutations in the Abl kinase domain. We herein examine the in vitro and in vivo effects of a Bcr-Abl/Lyn dual tyrosine kinase inhibitor, NS-187, on seven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f24b8f07eec25692cafe1b40c27e9e30
https://doi.org/10.1016/j.leukres.2006.01.006
https://doi.org/10.1016/j.leukres.2006.01.006
Autor:
Takeshi Yuasa, Junya Kuroda, Yuri Kamitsuji, Eri Kawata, Kiyoshi Sato, Tomoko Niwa, Shinya Kimura, Asumi Yokota, Hidekazu Segawa, Tetsuo Asaki, Kazuko Hirabayashi, Taira Maekawa, Haruna Naruoka, Yohei Nakaya, Eishi Ashihara, Haruna Naito, Tatsushi Wakayama, Kimio Nasu
Publikováno v:
Blood. 106:3948-3954
Although the Abelson (Abl) tyrosine kinase inhibitor imatinib mesylate has improved the treatment of breakpoint cluster region–Abl (Bcr-Abl)–positive leukemia, resistance is often reported in patients with advanced-stage disease. Although several
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e65e481dcc9d49213c195ecff04fc754
https://doi.org/10.1182/blood-2005-06-2209
https://doi.org/10.1182/blood-2005-06-2209
Publikováno v:
Molecular and Cellular Biology. 24:3277-3285
Rad9 is required for the activation of DNA damage checkpoint pathways in budding yeast. Rad9 is phosphorylated after DNA damage in a Mec1- and Tel1-dependent manner and subsequently interacts with Rad53. This Rad9-Rad53 interaction has been suggested
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::716c369168eac248ac3ab85b616eaab4
https://doi.org/10.1128/mcb.24.8.3277-3285.2004
https://doi.org/10.1128/mcb.24.8.3277-3285.2004
Recruitment of Mec1 and Ddc1 checkpoint proteins to double-strand breaks through distinct mechanisms
Publikováno v:
Science (New York, N.Y.). 294(5543)
In response to DNA damage, eukaryotic cells activate checkpoint pathways that arrest cell cycle progression and induce the expression of genes required for DNA repair. In budding yeast, the homothallic switching (HO) endonuclease creates a site-speci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9b0e0874d5d3917219811a749b7f80e
https://pubmed.ncbi.nlm.nih.gov/11679674
https://pubmed.ncbi.nlm.nih.gov/11679674
Autor:
Tatsushi Wakayama, Shinsaku Ito, Haruna Naruoka, Haruna Naito, Kazuko Hirabayashi, Taira Maekawa, Sachie Kimura, Yohei Nakaya, Eishi Ashihara, Shinya Kimura
Publikováno v:
Blood. 106:1518-1518
We have identified a specific dual Bcr-Abl/Lyn inhibitor, NS-187 (elsewhere described as CNS-9), which is 25–55 times more potent than imatinib against wild type Bcr-Abl in vitro. To evaluate the potential of NS-187 as a therapeutic agent, we asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::385db3979dcf8944c5978ac8cd584614
https://doi.org/10.1182/blood.v106.11.1518.1518
https://doi.org/10.1182/blood.v106.11.1518.1518
Autor:
Haruna Naito, Asumi Yokota, Kazuko Hirabayashi, Taira Maekawa, Haruna Naruoka, Eishi Ashihara, Tatsushi Wakayama, Yuri Kamitsuji, Tetsuo Asaki, Yohei Nakaya, Eri Kawata, Shinya Kimura, Tomoko Niwa
Publikováno v:
Blood. 106:1522-1522
Chemical modifications of imatinib mesylate made with the guidance of molecular modeling yielded several promising compounds. Among them, we selected a compound denoted NS-187 (elsewhere described as CNS-9) on the basis of its affinity to Abl, and al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7063d51bc1224749bea962bba659ded
https://doi.org/10.1182/blood.v106.11.1522.1522
https://doi.org/10.1182/blood.v106.11.1522.1522